Browse by author
Lookup NU author(s): Dr Lina Hamadeh, Dr Amir EnshaeiORCiD, Claire Schwab, Professor Christine Harrison FRCPath FMedSci, Professor Anthony MoormanORCiD
This is the final published version of an article that has been published in its final definitive form by American Society of Hematology, 2019.
For re-use rights please refer to the publisher's terms and conditions.
Genetic abnormalities provide vital diagnostic and prognostic information in pediatric acute lymphoblastic leukemia (ALL) and are increasingly used to assign patients to risk groups. We recently proposed a novel classifier based on the copy-number alteration (CNA) profile of the 8 most commonly deleted genes in B-cell precursor ALL. This classifier defined 3 CNA subgroups in consecutive UK trials and was able to discriminate patients with intermediate-risk cytogenetics. In this study, we sought to validate the United Kingdom ALL (UKALL)–CNA classifier and reevaluate the interaction with cytogenetic risk groups using individual patient data from 3239 cases collected from 12 groups within the International BFM Study Group. The classifier was validated and defined 3 risk groups with distinct event-free survival (EFS) rates: good (88%), intermediate (76%), and poor (68%) (P < .001). There was no evidence of heterogeneity, even within trials that used minimal residual disease to guide therapy. By integrating CNA and cytogenetic data, we replicated our original key observation that patients with intermediate-risk cytogenetics can be stratified into 2 prognostic subgroups. Group A had an EFS rate of 86% (similar to patients with good-risk cytogenetics), while group B patients had a significantly inferior rate (73%, P < .001). Finally, we revised the overall genetic classification by defining 4 risk groups with distinct EFS rates: very good (91%), good (81%), intermediate (73%), and poor (54%), P < .001. In conclusion, the UKALL-CNA classifier is a robust prognostic tool that can be deployed in different trial settings and used to refine established cytogenetic risk groups.https://doi.org/10.1182/bloodadvances.2018025718
Author(s): Hamadeh L, Enshaei A, Schwab C, Alonso CN, Attarbaschi A, Barbany G, den Boer ML, Boer JM, Braun M, Dalla Pozza L, Elitzur S, Emerenciano M, Fechina L, Felice MS, Fronkova E, Haltrich I, Heyman MM, Horibe K, Imamura T, Jeison M, Kovács G, Kuiper RP, Mlynarski W, Nebral K, Ivanov Öfverholm I, Pastorczak A, Pieters R, Piko H, Pombo-de-Oliveira MS, Rubio P, Strehl S, Stary J, Sutton R, Trka J, Tsaur G, Venn N, Vora A, Yano M, Harrison CJ, Moorman AV
Publication type: Article
Publication status: Published
Journal: Blood Advances
Year: 2019
Volume: 3
Issue: 2
Pages: 148-157
Print publication date: 16/01/2019
Acceptance date: 06/12/2018
Date deposited: 03/05/2019
ISSN (electronic): 2473-9529
Publisher: American Society of Hematology
URL: https://doi.org/10.1182/bloodadvances.2018025718
DOI: 10.1182/bloodadvances.2018025718
Altmetrics provided by Altmetric
